Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P (2000) Blood 95: 564-8 Detection of factor X activation in humans. Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD (1989) Blood 74: 2007-15 A cross-sectional study of bleeding phenotype in haemophilia A carriers. Paroskie A, Gailani D, DeBaun MR, Sidonio RF (2015) Br J Haematol 170: 223-8 Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy. Keravala A, Chavez CL, Hu G, Woodard LE, Monahan PE, Calos MP (2011) Gene Ther 18: 842-8 Females with FVIII and FIX deficiency have reduced joint range of motion. Sidonio RF, Mili FD, Li T, Miller CH, Hooper WC, DeBaun MR, Soucie M, Hemophilia Treatment Centers Network (2014) Am J Hematol 89: 831-6 Haemophilia A carriers experience reduced health-related quality of life. Gilbert L, Paroskie A, Gailani D, Debaun MR, Sidonio RF (2015) Haemophilia 21: 761-5 Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes. Gilbert L, Rollins L, Hilmes M, Luo Y, Gailani D, Debaun MR, Sidonio RF (2014) Haemophilia 20: e426-9 Both hemophilia health care providers and hemophilia a carriers report that carriers have excessive bleeding. Paroskie A, Oso O, Almassi B, DeBaun MR, Sidonio RF (2014) J Pediatr Hematol Oncol 36: e224-30
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.